Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
Clinical trial NCT07686926 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07686926
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2028-07-31
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.